On June 16, Innoscience (02577.HK) fell 3.19% in regular trading, trading at 65.2 HKD/share, with turnover of HKD 175 million. The decline comes as profit-taking emerges following a sharp rally driven by the company's landmark patent victory over Infineon.

On June 12, China's Supreme People's Court upheld the Suzhou Intermediate Court's sales injunction against Infineon, banning Infineon's GaN products from sale, import, and distribution in China. This ruling validated Innoscience's two core GaN patents and is expected to create a RMB 2.8-3.0 billion annual market gap for domestic players to fill.

However, persistent selling pressure from the company's H-share full circulation continues to weigh on sentiment. Approximately 374 million previously unlisted domestic shares were converted to tradable H-shares, with early private equity investors still sitting on substantial unrealized gains. Additionally, STMicroelectronics' cornerstone allocation of approximately 12.59 million shares is set to unlock on June 29, further dampening near-term appetite. Institutional shareholders including China Merchants Bank International have recorded multiple recent disposals according to HKEX filings.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)